Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents

Nature Medicine

Volumn 22, Issue 7, 2016, Pages 800-806

  Scarlett, Jarrad M ^a,b   Rojas, Jennifer M ^a   Matsen, Miles E ^a   Kaiyala, Karl J ^a   Stefanovski, Darko ^c   Bergman, Richard N ^d   Nguyen, Hong T ^a   Dorfman, Mauricio D ^a   Lantier, Louise ^e   Wasserman, David H ^e   Mirzadeh, Zaman ^f   Unterman, Terry G ^g,h   Morton, Gregory J ^a   Schwartz, Michael W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BARROW NEUROLOGICAL INSTITUTE   (United States)

^g UNIVERSITY OF ILLINOIS   (United States)

^h Jesse Brown Virginia Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 5; GLUCOSE; HEAT SHOCK PROTEIN 27; PROTEIN C FOS; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 1; RECOMBINANT FIBROBLAST GROWTH FACTOR 19; UNCLASSIFIED DRUG; CARBON; DEOXYGLUCOSE; FIBROBLAST GROWTH FACTOR 1; FOXO1 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; HEAT SHOCK PROTEIN; HSPB1 PROTEIN, MOUSE; INSULIN RECEPTOR; TRANSCRIPTION FACTOR FKHR; TUMOR PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; ASTROCYTE; BLOOD; CLEARANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTHALAMUS; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REMISSION; SINGLE DRUG DOSE; TANYCYTE; WEIGHT REDUCTION; ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY COMPOSITION; BRAIN; CARDIAC MUSCLE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLUCOSE TOLERANCE TEST; HEART; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; KNOCKOUT MOUSE; LIPID DIET; LIVER; MACROGLIA; METABOLISM; MOUSE MUTANT; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; WESTERN BLOTTING; ZUCKER RAT;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; BODY COMPOSITION; BRAIN; CARBON RADIOISOTOPES; DEOXYGLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; EPENDYMOGLIAL CELLS; FIBROBLAST GROWTH FACTOR 1; FORKHEAD BOX PROTEIN O1; GLUCOSE TOLERANCE TEST; HEART; HEAT-SHOCK PROTEINS; HYPERGLYCEMIA; HYPOTHALAMUS; INJECTIONS, INTRAVENTRICULAR; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, OBESE; MUSCLE, SKELETAL; MYOCARDIUM; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, ZUCKER; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, INSULIN; REMISSION INDUCTION;

EID: 84969791239     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4101     Document Type: Article

References (45)

1. International Diabetes Federation. IDF Diabetes Atlas 7th edn. (International Diabetes Federation, Brussels, Belgium, 2015).
2. Morton, G.J. et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 123, 4799-4808 (2013).
3. Marcelin, G. et al. Central action of FGF19 reduces hypothalamic AgRP/NPY neuron activity and improves glucose metabolism. Mol. Metab. 3, 19-28 (2014).
4. Ryan, K.K. et al. Fibroblast growth factor 19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154, 9-15 (2013).
5. Ornitz, D.M. and Itoh, N. The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4, 215-266 (2015).
6. Schwartz, M.W. et al. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature 503, 59-66 (2013).
7. Grayson, B.E., Seeley, R.J. and Sandoval, D.A. Wired on sugar: the role of the CNS in the regulation of glucose homeostasis. Nat. Rev. Neurosci. 14, 24-37 (2013).
8. Fu, L. et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145, 2594-2603 (2004).
9. Xu, J. et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297, E1105-E1114 (2009).
10. Suh, J.M. et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 513, 436-439 (2014).
11. Ito, J. et al. Astrocytes produce and secrete FGF1, which promotes the production of apoE-HDL in a manner of autocrine action. J. Lipid Res. 46, 679-686 (2005).
12. Oomura, Y. et al. A new brain glucosensor and its physiological significance. Am. J. Clin. Nutr. 55 (suppl. 1), 278S-282S (1992).
13. Suzuki, S. et al. Feeding suppression by fibroblast growth factor 1 is accompanied by selective induction of heat-shock protein 27 in hypothalamic astrocytes. Eur. J. Neurosci. 13, 2299-2308 (2001).
14. Lou, G. et al. Intranasal administration of TAT-haFGF14-154 attenuates disease progression in a mouse model of Alzheimers disease. Neuroscience 223, 225-237 (2012).
15. Cheng, X. et al. Acidic fibroblast growth factor delivered intranasally induces neurogenesis and angiogenesis in rats after ischemic stroke. Neurol. Res. 33, 675-680 (2011).
16. Jonker, J.W. et al. A PPAR-γ-FGF1 axis is required for adaptive adipose remodeling and metabolic homeostasis. Nature 485, 391-394 (2012).
17. Perry, R.J. et al. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat. Commun. 6, 6980 (2015).
18. Best, J.D., Taborsky, G.J. Jr., Halter, J.B. and Porte, D. Jr. Glucose disposal is not proportional to plasma glucose level in man. Diabetes 30, 847-850 (1981).
19. Kahn, S.E. et al. The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes 43, 587-592 (1994).
20. Gresl, T.A. et al. Dietary restriction and glucose regulation in aging rhesus monkeys: a follow-up report at 8.5 years. Am. J. Physiol. Endocrinol. Metab. 281, E757-E765 (2001).
21. Ader, M., Pacini, G., Yang, Y.J. and Bergman, R.N. Importance of glucose per se to intravenous glucose tolerance. Comparison of the minimal-model prediction with direct measurements. Diabetes 34, 1092-1103 (1985).
22. Alonso, L.C. et al. Simultaneous measurement of insulin sensitivity, insulin secretion, and the disposition index in conscious unhandled mice. Obesity (Silver Spring) 20, 1403-1412 (2012).
23. Rojas, J.M. et al. Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response. Mol. Metab. 4, 561-568 (2015).
24. Stefanovski, D. et al. Estimating hepatic glucokinase activity using a simple model of lactate kinetics. Diabetes Care 35, 1015-1020 (2012).
25. Davis, M.A., Williams, P.E. and Cherrington, A.D. Net hepatic lactate balance following mixed meal feeding in the 4-d fasted conscious dog. Metabolism 36, 856-862 (1987).
26. King, A.J. The use of animal models in diabetes research. Br. J. Pharmacol. 166, 877-894 (2012).
27. Porte, D. Jr. Banting lecture 1990. Beta cells in type 2 diabetes mellitus. Diabetes 40, 166-180 (1991).
28. Schaffer, L. et al. A novel high-affinity peptide antagonist to the insulin receptor. Biochem. Biophys. Res. Commun. 376, 380-383 (2008).
29. Lu, M. et al. Insulin regulates liver metabolism in vivo in the absence of hepatic AKT and FOXO1. Nat. Med. 18, 388-395 (2012).
30. O-Sullivan, I. et al. FOXO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat. Commun. 6, 7079 (2015).
31. Titchenell, P.M., Chu, Q., Monks, B.R. and Birnbaum, M.J. Hepatic insulin signaling is dispensable for suppression of glucose output by insulin in vivo. Nat. Commun. 6, 7078 (2015).
32. Orellana, J.A. et al. Glucose increases intracellular free Ca2+ in tanycytes via ATP released through connexin 43 hemichannels. Glia 60, 53-68 (2012).
33. Robins, S.C. et al. α-Tanycytes of the adult hypothalamic third ventricle include distinct populations of FGF-responsive neural progenitors. Nat. Commun. 4, 2049 (2013).
34. Stetler, R.A., Gao, Y., Signore, A.P., Cao, G. and Chen, J. HSP27: mechanisms of cellular protection against neuronal injury. Curr. Mol. Med. 9, 863-872 (2009).
35. Mirzadeh, Z., Doetsch, F., Sawamoto, K., Wichterle, H. and Alvarez-Buylla, A. The subventricular zone en-face: whole-mount staining and ependymal flow. J. Vis. Exp. 39, 1938 (2010).
36. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M. and Tsai, L.H. Recovery of learning and memory is associated with chromatin remodeling. Nature 447, 178-182 (2007).
37. Pinto, J.G., Jones, D.G., Williams, C.K. and Murphy, K.M. Characterizing synaptic protein development in human visual cortex enables alignment of synaptic age with rat visual cortex. Front. Neural Circuits 9, 3 (2015).
38. Moore, M.C., Coate, K.C., Winnick, J.J., An, Z. and Cherrington, A.D. Regulation of hepatic glucose uptake and storage in vivo. Adv. Nutr. 3, 286-294 (2012).
39. Elizondo-Vega, R. et al. The role of tanycytes in hypothalamic glucosensing. J. Cell. Mol. Med. 19, 1471-1482 (2015).
40. Bolborea, M. and Dale, N. Hypothalamic tanycytes: potential roles in the control of feeding and energy balance. Trends Neurosci. 36, 91-100 (2013).
41. National Research Council. Guide for the Care and Use of Laboratory Animals 8th edn. (The National Academies Press, 2011).
42. Paxinos, G. and Watson, C. The Rat Brain in Stereotaxic Coordinates (Academic Press, San Diego, California, USA, 1998).
43. Franklin, K.B.J. and Paxinos, G. The Mouse Brain in Stereotaxic Coordinates (Academic Press, San Diego, California, USA, 1997).
44. Ayala, J.E., Bracy, D.P., McGuinness, O.P. and Wasserman, D.H. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55, 390-397 (2006).
45. Otero, Y.F. et al. Enhanced glucose transport but not phosphorylation capacity ameliorates lipopolysaccharide-induced impairments in insulin-stimulated muscle glucose uptake. Shock http://dx.doi.org/10.1097/SHK.0000000000000550 (2015).